- New ETFs
- Bond ETFs
- Currency ETFs
- Emerging Market ETFs
- Commodity ETFs
- Broad U.S. Equity ETFs
- Sector ETFs
- Specialty ETFs
NASDAQ Warns It Could Delist Cyclacel
Posted on 12/15/09 at 6:47pm by Eric Bosco
Cyclacel Pharmaceuticals (NASDAQ: CYCC)(FREE stock trend analysis) said it received notice from the exchange stating that its shares face the prospect of delisting.
At issue is the company’s failure to comply with NASDAQ’s $10 million shareholder equity minimum requirement.
Cyclacel said it will request a hearing with the exchange in order to address these concerns.
CYCC shares dropped 12 cents to close at $1.24 in trading today. Despite that, the stock is above the midpoint in its one-year trading range.
Bookmark/Search this post with:
Related Articles
Today's Trading Ideas
Featured Articles
Related News from the Stock Market
- Biotech Stock Alert for Cyclacel Pharmaceuticals Inc. Issued by InvestorSoup
- Cyclacel Pharmaceuticals to Announce Fourth Quarter 2009 Financial Results on March 23, 2010
- Cyclacel Pharmaceuticals to Present at the 22nd Annual ROTH Capital OC Growth Stock Conference
- Benzinga’s Top Pre-Market Gainers (CSTR, DE, DVN, CYCC, NLST)
- New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel's Seliciclib in Treating Breast Cancer Resistant to Hormone Therapy
There are 0 comments
Please note that comments may take up to one hour before they get published on the site. Please check back later to see your comments.
Post new comment
Receive Benzinga's Best 2010 Stock Idea!
